According to reports, the combination of GSK-3β inhibitors with chemotherapy is strategically poised to be a promising approach to overcome the emergence of early drug resistance or to overcome chemoresistance in advanced and metastatic pancreatic tumors [24]. The gene discussed is GSK3B; the disease is pancreatic neoplasm.